Description
Pegilodecakin (also known as LY3500518) is an investigational drug being studied by Eli Lilly and Company. It is currently in early-phase clinical trials (Phase 1) for advanced solid tumors, including colorectal cancer. These trials are primarily focused on determining the safe dosage and how patients tolerate the drug, both when given alone (monotherapy) and in combination with standard chemotherapy (like 5-Fluorouracil, Capecitabine, Leucovorin, Oxaliplatin, Paclitaxel) or immunotherapy (like Nivolumab, Pembrolizumab). Pegilodecakin is being investigated as a potential treatment option for advanced colorectal cancer, but it is not yet approved for use.
Mechanism of Action
Pegilodecakin is being studied as a targeted therapy. The specific way it works (its molecular target) is still being investigated in clinical trials. It is designed to interfere with processes that help cancer cells grow and survive. It is a type of protein that is being evaluated for its potential to treat cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.